A practical reference on GIP receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Mayer's reagent is an alkaloidal precipitating reagent used for the detection of alkaloids in natural products. Mayer's reagent is freshly prepared by dissolving a mixture of mercuric chloride (1.36 g) and of potassium iodide (5.00 g) in water (100.0 ml). Most alkaloids are precipitated from neutral or slightly acidic solution by Mayer's reagent (potassiomercuric iodide solution) to give a cream coloured precipitate. This test was invented by and named after the German chemist Julius Robert Von Mayer (1814–1878). Can be used as a visualization reagent in thin-layer chromatography (TLC) for the detection of alkaloids.
== Applications == Hafnium isomers (mainly 178m2Hf) have been considered as weapons that could be used to circumvent the Nuclear Non-Proliferation Treaty, since it is claimed that they can be induced to emit very strong gamma radiation. This claim is generally discounted. DARPA had a program to investigate this use of both nuclear isomers. The potential to trigger an abrupt release of energy from nuclear isotopes, a prerequisite to their use in such weapons, is disputed. Nonetheless a 12-member Hafnium Isomer Production Panel (HIPP) was created in 2003 to assess means of mass-producing the isotope. Technetium isomers 99m43Tc (with a half-life of 6.01 hours) and 95m43Tc (with a half-life of 61 days) are used in medical and industrial applications.
In November 2025, YouTube terminated Peters' original channel for facilitating access to websites selling regulated goods, canceling two additional channels in April 2026 for "severe or repeated violations." Although he attempted to return to the platform with other channels, YouTube permanently terminated these accounts in April 2026, citing a violation of its terms of service regarding ban evasion. A November 2025 video of him injecting his then 17-year-old girlfriend with fat-dissolving peptides to reshape her jaw gained attention online. In a later stream, he injected influencer Jenny Popach with Aqualyx, a fat-dissolving acid. On December 27, 2025, Peters appeared in an interview with conservative political commentator Michael Knowles for The Daily Wire. In it, Peters described Vice President JD Vance as "subhuman" for his "recessed side profile" and for being "obese", asking, "How are you fat and expected to lead a country?" He agreed with Knowles's criticism of California governor Gavin Newsom as both a "degenerate" and a "liar" but said that, in a potential 2028 United States presidential election in which Newsom ran against Vance, he would vote for "Chad" Newsom for "mogging" (being more attractive than) Vance. The segment soon went viral online. Other clips of him from the interview, including one in which he described actress Sydney Sweeney as "malformed" with an "extremely recessed" upper maxilla and "eyes of doom with no infraorbital support", also went viral online.
Wild non-Saccharomyces yeasts often need a much greater exposure to oxygen in order to build up survival factors which is why many of these yeasts are often found living oxidatively as "film yeast" on the surface of wines in tanks or barrels.
Sources: en.wikipedia.org
==== Blood tests ==== Blood tests play an important role in the diagnosis and treatment of many cardiovascular conditions. Troponin is a sensitive biomarker for a heart with insufficient blood supply. It is released 4–6 hours after injury and usually peaks at about 12–24 hours. Two tests of troponin are often taken—one at the time of initial presentation and another within 3–6 hours, with either a high level or a significant rise being diagnostic. A test for brain natriuretic peptide (BNP) can be used to evaluate for the presence of heart failure, and rises when there is increased demand on the left ventricle. These tests are considered biomarkers because they are highly specific for cardiac disease. Testing for the MB form of creatine kinase provides information about the heart's blood supply, but is used less frequently because it is less specific and sensitive. Other blood tests are often taken to help understand a person's general health and risk factors that may contribute to heart disease. These often include a full blood count investigating for anaemia, and basic metabolic panel that may reveal any disturbances in electrolytes. A coagulation screen is often required to ensure that the right level of anticoagulation is given. Fasting lipids and fasting blood glucose (or an HbA1c level) are often ordered to evaluate a person's cholesterol and diabetes status, respectively.
In 1776 the Continental Army constructed an array of logs sunk underwater between Fort Washington on the island of Manhattan and Fort Lee across the river in New Jersey. Built to a design of Scottish engineer turned Colonial sympathizer Robert Erskine, the logs were intended to pierce and sink any British ships that passed over them. An opening was left for the passage of American ships. After the British learned of the opening from a local resident, they successfully passed through the barrier several times. The British successfully captured both forts in the Battle of Fort Washington on November 16, 1776, and Battle of Fort Lee on November 20, putting the defensive barrier in their hands. This change had little impact, as the nascent Continental Navy lacked ships of the size and power of the British, leaving it to resort to small and more maneuverable vessels regardless.
Guided bone regeneration is similar to guided tissue regeneration, but is focused on development of hard tissues in addition to the soft tissues of the periodontal attachment. At present, guided bone regeneration is predominantly applied in the oral cavity to support new hard tissue growth on an alveolar ridge to allow stable placement of dental implants. When bone grafting is used in conjunction with sound surgical technique, guided bone regeneration is a reliable and validated procedure.
== External links == Media related to Zearalenone at Wikimedia Commons Eriksen GS, Pennington J, Schlatter J (2000). "Zearalenone". WHO International Programme on Chemical Safety - Safety Evaluation of Certain Food Additives and Contaminants. Inchem. WHO Food Additives Series.
5 March South Vietnamese Prime Minister, Tran Van Huong, narrowly escaped assassination by a four man VC team as he was being driven to his home in Saigon. Huong's car was attacked by the VC who were wearing stolen Ranger uniforms, however Saigon police and ARVN troops opened fire and gave the driver time to accelerate and escape. The PAVN/VC fired seven rockets into Saigon killing 22 civilians.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.